Virale hepatitis

Steenbergen JE van, Tjon G, Hoek JAR van den, Koek A, Coutinho RA, Bruisten SM. Two years’ prospective collection of molecular and epidemiological data shows limited spread of hepatitis A outside risk groups in Amsterdam 2000-2002. J Infect Dis 2004;189(3):471-82.

Gorkom J van, Leentvaar-Kuijpers A, Kool JL, Coutinho RA. Jaarlijkse epidemie van hepatitis A in verband gebracht met reisgedrag van kinderen van immigranten in de vier grote steden. Ned Tijdschr Geneeskd 1998;142:1919-23.

Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, et al. Prevalence of hepatitis A, B and C in the Flemish population. European Journal of Epidemiology 1997;13:275-280.

Termorshuizen F, Dongo-Zetsma JW, Melker HE de, Hof S van den, Conyn-Van Spaendonck MA. The prevalence of antibodies to HAV virus and its determinants in The Netherlands: a population-bases survey. Epidemiol Infect 2000;124:49-66.

Gezondheidsraad. Algemene vaccinatie tegen hepatitis B. Den Haag: Gezondheidsraad; 2001. Publicatie nr 2001/03, ISBN 90-5549-359-7.

Van Loock F, Rubbens C. Rapport d’enquête sur la prevalence de l’hépatite B en Communauté française de Belgique. Bruxelles: Institut d’Hygiène et d’Epidémiologie; 1994. D/1994/2505/24.

EASL International Consensus Conference on hepatitis B, 13-14 September, 2002, Geneva, Switzerland. Consensus statement (Long version). J Hepatol 2003;39:S3-S25.

Hsu Y, Chien R, Yeh C, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous hbeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-7.

Wong D, Cheung A, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993;119:312-23.

Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of hbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.

Oliveri F, Santantonio T, Bellati G, Colombatto P, Mels GC, Carriero L, et al. Long term response to therapy of chronic anti-Hbe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999;94:1366-72.

Cooksley WGE, Piratvisuth T, Lee SD, Mahalachai V, Chao Y-C, Tanwandee T, et al. Peginterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.

Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a ­alone, lamivudine alone, and the two in combination in patients with hbeAg-negative chronic hepatitis B. N Engl J Med 2004;351:31-43.

Lai CL, Chien RW, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronc hepatitis B. N Engl J Med 1998;339:61-8.

Dienstag JL, Schiff E, Wright T, Hann HI, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.

Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000;46:562-8.

Schiff E, Karayalcin S, Grimm I, Perillo R, Dienstag J, Husa P, et al. A placebo controlled study of lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998;28 (Suppl.):388A.

Leung YF, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-32.

Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KI, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.

Tassopoulos N, Volpes R, Pastore G, Heathcote J, Buti M, Goldin BD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus dna positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96.

Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovirdipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.

Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Jain A, et al. Adefovirdipivoxil (adv) 10 mg for the treatment of patients with hbeAg+ chronic hepatitis B: continued efficacy beyond 48 weeks. Hepatology 2002;36:373A.

Qi X, Snow A, Thibault V, Zhu Y, Curtis M, Hadziyannis SJ, et al. Long-term incidence of Adefovirdipivoxil (adv) resistance in chronic hepatitis B (chb) patients after 144 weeks of therapy. J Hepatol 2004; 40 (Suppl. 1), 20-1.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chan TT, Kitis G, Rizzetto M, et al. Adefovirdipivoxil for the treatment of hepatitis B e antigen negative hepatitis B. N Engl J Med 2003;348:800-7.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chan TT, Kitis G, Rizzetto M, et al. Long-term therapy with Adefovirdipivoxil for Hbeag-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81.

Peters MG, Hann H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovirdipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.

Vranckx R, Walckiers D, Stroobants A, Thiers G. Seroepidemiological characteristics of hepatitis C encountered in general practice in Belgium. Eur J Clin Microbiol Infect Dis 1992;11:62-4.

Devroey D, Casteren V, Vranckx R. Evolutie van de incidentie van klinische acute virale hepatitis in de Belgische huisartsenpraktijk. Registratienet van de huisartsenpeilpraktijken – resultaten van 1991 en 1992. Rapport. Brussel: Instituut voor Hygiene en Epidemiologie; 1997.

Letaïef H. Hépatite C en Belgique: Seroprévalence et facteurs de risque. Thesis. Z.p.: Institute of Tropical Medicine, 1995. IMTA/MScBT/C7 1995, n° 10.

Matheï C, Robaeys G, Van Ranst M, Van Damme P, Buntinx F. The epidemiology of hepatitis C among injecting drug users in Belgium. Acta Gastro-Enterologica Belgica 2005;68:50-4.

Gezondheidsraad, Commissie Hepatitis C. Opsporing en behandeling van mensen met hepatitis C. Rijswijk: Gezondheidsraad; 1997. Publicatie nr. 1997/19.

Gezondheidsraad. Briefadvies Opsporing en behandeling van mensen met hepatitis C. Den Haag: Gezondheidsraad, 2004. Publicatie nr. 2004/17.

Davis GL, Albright JE, Cook S, Rosenberg D. Projecting the future healthcare burden from hepatitis C in the United States. Hepatology 1998;28:390A.

Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-82.

Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-7.

Delwaide J, Bourgeois N, Gerard C, De Maeght S, Mokkadem F, Wain E, et al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004;20:15-22.

NIH Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997:26(Suppl 1):2S-10S.

Strader DB, Wright T, Thomas DL, Seef LB. AASLD Practice Guideline: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.

Consensus Conference. Treatment of chronic hepatitis C. Gastroenterol Clin Biol 2002;26: B303-­B319.

Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peg­interferon alfa-2b and ribavirin. Hepatology 2003;38:481-92.

Zeuzem S, Diago M, Gane E, Reddy R, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-32.

Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic hcv-rna in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.

Fried MW, Shiffman M, Reddy KR, Smith C, Marinos G, Goncalez FRJr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.

Hadziyannis SJ, Sette HJr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination treatment in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.

Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.